Next-Gen Antibody Engineering for GPCRs by Integrating Autonomous Yeast Display and AI
Sponsored by Aureka Biotechnologies
Traditional antibody discovery and optimization is often unpredictable and costly. AuraQuest™ utilizes yeast surface display and autonomous hypermutation to mimic animal immunization, enabling rapid antibody discovery. Combined with the AI platform AuraPicasso™, this approach accelerates the engineering of antibodies with specific characteristics. This method has effectively targeted challenging antigens like GPCRs, demonstrating potent nanobody isolation within two weeks through affinity maturation using yeast culturing and FACS.
Aureka Biotechnologies is a premier biotech startup committed to democratizing the pharmaceutical industry to defeat disease. Aureka is developing a best-in-class therapeutic discovery platform that uniquely integrates high-throughput, single-cell-based functional screening, synthetic biology-based autonomous discovery, and generative AI-based therapeutic design and multi-objective optimization. Empowered by large-scale, multi-metric data generated at an unprecedented scale and rapid reinforcement learning, Aureka’s AI solutions can uncover therapeutic design principles and exponentially accelerate the discovery of a wide range of immunotherapeutic modalities including bispecific antibodies, ADCs, TCR-T, as well as new therapeutics for previously challenging targets and mechanisms such as GPCR.
Learning Objectives:
• In this webinar, you will explore how we combine cutting-edge synthetic biology with established display technologies to overcome the challenges and limitations in antibody discovery. We will demonstrate how our experimental and AI platforms accelerate the engineering of antibodies with specific characteristics, particularly for challenging targets like GPCRs. Additionally, you'll gain insights into successful case studies and discover why Aureka could be your top choice for partnering to develop best-in-class antibody therapeutics.
Privacy Policy
